Norimin (Ethinylestradiol, Norethisterone)

Norimin, a combined oral contraceptive, is indicated for hormonal regulation of the reproductive system.

• Prevention of pregnancy: Provides reliable contraception by inhibiting ovulation and altering cervical mucus.
• Menstrual cycle regulation: Helps achieve more predictable bleeding patterns and reduces dysmenorrhea.

• Norimin combines ethinylestradiol, a synthetic estrogen, with norethisterone, a progestogen. The estrogen component suppresses the mid‑cycle surge of luteinizing hormone, while the progestogen inhibits follicular development and stabilizes the endometrium. Together they prevent ovulation, thicken cervical mucus to impede sperm penetration, and induce endometrial changes that reduce the likelihood of implantation. These coordinated actions maintain a hormonal environment unsuitable for conception throughout the monthly cycle.

Norimin may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Nausea: mild stomach upset, especially when starting therapy.
• Headache: transient tension‑type headaches.
• Breast tenderness: mild swelling or discomfort.
• Spotting: irregular breakthrough bleeding.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Hypertension: significant increase in blood pressure.
• Liver dysfunction: jaundice or abnormal liver enzymes.
• Severe allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Norimin, clinicians should evaluate patient risk factors and provide counseling on safe use.

• Assess cardiovascular risk: evaluate history of thrombosis, hypertension, or smoking.
• Screen for liver disease: avoid use in active liver disease.
• Contraindicated in pregnancy: discontinue immediately if pregnancy occurs.
• Consider age and smoking status: women over 35 who smoke have increased risk of serious events.
• Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture.

Norimin can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Enzyme‑inducing anticonvulsants: carbamazepine, phenytoin, phenobarbital reduce hormonal efficacy.
• Rifampicin antibiotics: lower plasma concentrations of both hormones.
• Protease inhibitor antiretrovirals: unpredictable hormone levels may compromise contraception.

Moderate Interactions (Monitor Closely)

• Antifungal agents (ketoconazole, itraconazole): may increase hormone levels and side‑effect risk.
• St. John’s wort herbal supplement: may decrease contraceptive effectiveness.
• Selective serotonin reuptake inhibitors (paroxetine, fluoxetine): may increase bleeding risk.